InvestorsHub Logo
Followers 827
Posts 119484
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 186

Tuesday, 05/10/2022 6:02:32 PM

Tuesday, May 10, 2022 6:02:32 PM

Post# of 245
EOLS 1Q22 product_sales=$33.2M—3/31/22_cash=$106.7M—(down from $146.3M @12/31/21):

https://investors.evolus.com/press-releases-and-news/news-details/2022/Evolus-Reports-First-Quarter-2022-Results-and-Provides-Business-Update/default.aspx

1Q22 Jeuveau sales of $33.2 (including $0.7M in Canada) were -2% QoQ, consistent with seasonal trends in the aesthetics business.

EOLS now expects 2022 Jeuveau sales to be at the high end of the prior guidance range of $143-150M, but this won’t be enough to reach breakeven operations.

EOLS continues to expect the EU launch of Jeuveau/Nuceiva in 3Q22.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EOLS News